AgeX Therapeutics, Inc. (AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.
AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova”), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx”), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem”), for ImStem to utilize AgeX’s ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.
We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology,” said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.”
AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.
AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far,” said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.”
Q2 Highlights
Liquidity and Capital Resources
AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement”) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescence’s discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeX’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.
On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan”). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP”) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses”), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.
Staff Reductions
In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeX’s strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.
Going Concern Considerations
As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeX’s most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescence’s discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeX’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.
Second Quarter 2020 Operating Results
Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards® online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.
Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.
The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.
Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage”) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.
General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeX’s own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies in the body. AgeX’s core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will,” believes,” plans,” anticipates,” expects,” estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors” section of AgeX’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeX’s Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)
June 30, 2020
December 31, 2019
(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$
1,033
$
2,352
Accounts and grants receivable, net
235
363
Prepaid expenses and other current assets
836
1,339
Total current assets
2,104
4,054
Property and equipment, net
681
1,126
Deposits and other long-term assets
100
111
Intangible assets, net
1,872
2,151
TOTAL ASSETS
$
4,757
$
7,442
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued liabilities
$
1,771
$
1,582
Loan due to Juvenescence, net of debt issuance cost, current portion
1,821
-
Related party payables, net
142
64
Deferred revenues
328
283
Right-of-use lease liability
218
428
Paycheck Protection Program Loan
434
-
Insurance premium liability and other current liabilities
433
940
Total current liabilities
5,147
3,297
Loan due to Juvenescence, net of debt issuance cost, net of current portion
1,732
1,528
TOTAL LIABILITIES
6,879
4,825
Commitments and contingencies (Note 9)
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of June 30, 2020 and December 31, 2019
-
-
Common stock, $0.0001 par value, 100,000 shares authorized; 37,658 and 37,649 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
Read more here:
- Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform - FiercePharma - April 19th, 2024
- The Stem Cells Market expected to grow at the value of USD 28.1 Billion by 2030 with a 10.48% CAGR. - WhaTech - April 19th, 2024
- Scientists produce in vitro model of cell differentiation during early facial development - Phys.org - April 19th, 2024
- Somite: AI-Based Stem Cell Therapy Company Closes $5.3 Million In Funding - Pulse 2.0 - April 19th, 2024
- Paralyzed man who can walk again shows potential benefit of stem cell therapy - ABC News - April 5th, 2024
- Stem Cells Market Innovations Investigated by Industry Overview and Global Forecast - WhaTech - April 5th, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - University of Wisconsin-Madison - April 1st, 2024
- The PTM profiling of CTCF reveals the regulation of 3D chromatin structure by O-GlcNAcylation - Nature.com - April 1st, 2024
- Signatures of Autofluorescence Used To Study Stem Cells Aging in the Brain - Technology Networks - March 30th, 2024
- Two decades of embryonic stem cells: a historical overview - March 28th, 2024
- Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats - The Malaysian Reserve - March 26th, 2024
- Unlocking the mysteries of early human development through blastoid models - News-Medical.Net - March 24th, 2024
- Unlocking the Secrets of Aging: Researchers Reveal Key to Intestinal Balance - SciTechDaily - March 17th, 2024
- Human stem-cell-based therapy for Parkinson's disease proven safe PET - BioNews - March 13th, 2024
- Exploring the inner workings of stem cells: When location changes the message - Phys.org - March 9th, 2024
- Confronting IVF: Human Embryos Are Persons With a Right to Life - Walter Bradley Center for Natural and Artificial Intelligence - March 7th, 2024
- When Location Changes the Message - UConn Today - University of Connecticut - March 7th, 2024
- Distinct pathways drive anterior hypoblast specification in the implanting human embryo - Nature.com - March 6th, 2024
- In light of the Alabama court ruling, a look at the science of IVF : Short Wave - NPR - March 3rd, 2024
- The weird way Alabamas embryo ruling takes on artificial wombs - MIT Technology Review - February 25th, 2024
- Alabama's biggest hospital to suspend transfer of embryos after court ruling - ABC News - February 24th, 2024
- Stem Cells: FAQs Answered for Patients and Caregivers - Corporate Wellness Magazine - February 22nd, 2024
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells - Business Wire - February 22nd, 2024
- Breakthrough Stem Cell Treatments for Stroke Recovery: What You Need to Know - Medical Tourism Magazine - February 20th, 2024
- Global Cell Isolation Market Size To Worth USD 13.4 Billion By 2033 | CAGR of 12.5% - Yahoo Finance - February 20th, 2024
- The Mechanism of Positional Cues in Embryonic Development and Signaling Molecules in Cell Fate - Medriva - February 18th, 2024
- Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review - Cureus - February 5th, 2024
- CRISPR/Cas9-mediated deletion of a GA-repeat in human GPM6B leads to disruption of neural cell differentiation from ... - Nature.com - January 29th, 2024
- Global Human Embryonic Stem Cell Market Analysis 2024-2034: A Deep Dive into Applications, End-users, and ... - GlobeNewswire - January 26th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News - January 14th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 12th, 2024
- How Stem Cell Embryo Models Won Method of the Year - Technology Networks - January 12th, 2024
- Changing the public perception of human embryology - ESHRE - January 11th, 2024
- How the Human Body Regenerates New Cells Every Year - Laughing Squid - January 4th, 2024
- Lab-grown models of embryos increasingly resemble the real thing | Mint - Mint - January 4th, 2024
- Singapore should ban reproductive applications of synthetic human embryos - BioEdge - January 4th, 2024
- Machine learning-based estimation of spatial gene expression pattern during ESC-derived retinal organoid ... - Nature.com - December 21st, 2023
- The development of embryos may be less shaped by genes than we thought - New Scientist - December 21st, 2023
- Embryonic stem cell - Wikipedia - December 13th, 2023
- Researchers discover a mechanism that controls the identity of stem cells - Phys.org - December 9th, 2023
- 'Fascinating and completely unexpected': Tiny robots fix neurons - FierceBiotech - December 5th, 2023
- Establishment and characterization of matched immortalized human ... - Nature.com - December 5th, 2023
- Proteomic insights into the associations between obesity, lifestyle ... - BMC Medicine - December 5th, 2023
- New therapy can treat rare and hereditary diseases - ScienceNorway - December 5th, 2023
- Scientists Still Can't Be Trusted on Gene Editing - Progressive.org - December 5th, 2023
- Harvard Apparatus Regenerative Technology and Renowned ... - Yahoo Finance - December 5th, 2023
- 4.4 Million Funding Injection Fuels World-Class Bioscience Research Programme - India Education Diary - December 3rd, 2023
- A two-kinesin mechanism controls neurogenesis in the developing ... - Nature.com - December 3rd, 2023
- What happens when nature and cities collide - CNN - December 3rd, 2023
- Pro-Life This Week: December 1, 2023 | ALL - All.org - December 3rd, 2023
- A look at the international race to create human eggs and sperm in ... - NPR - December 1st, 2023
- Synthetic genetic circuits to uncover the OCT4 trajectories of ... - Science - December 1st, 2023
- Why the Novo Nordisk Foundation is betting big on stem cells - pharmaphorum - November 29th, 2023
- Charity Watchlist Helps Donors Ensure Their Year-End Gifts Don't ... - All.org - November 29th, 2023
- A green glowing monkey has been created in China. What were the ... - Genetic Literacy Project - November 29th, 2023
- Fetal Bovine Serum Market to reach USD 1.26 Bn by 2029, emerging at a CAGR of 5.3 percent according to a ne... - WhaTech Technology and Markets News - November 29th, 2023
- Implications of Gene Therapy in Dentistry and Periodontics: A ... - Cureus - November 27th, 2023
- Study shows how to treat hereditary, rare diseases - ETHealthWorld - November 27th, 2023
- Drugs identified that may reverse brain fog caused by COVID-19 - New Atlas - November 27th, 2023
- The genes that made us truly human may also make us ill - BBC.com - November 25th, 2023
- Therapy to treat rare, hereditary diseases: Study - Hindustan Times - November 25th, 2023
- How the growth of a giant single cell is intertwined with daily self-rhythms - Phys.org - November 25th, 2023
- On this day: Mahmoud Abbas becomes leader of Fatah in 2004 - In-Cyprus - November 25th, 2023
- Evaluation of A-ring hydroxymethylene-amino- triterpenoids as ... - Nature.com - November 25th, 2023
- Disruption of the autism gene and chromatin regulator KDM5A alters ... - Science - November 23rd, 2023
- Scientists Created a Monkey With Two Different Sets of DNA - Smithsonian Magazine - November 23rd, 2023
- Genomic tug of war could boost cancer therapy - Science Daily - November 23rd, 2023
- What are stem cells? Throw light on various types of stem cells and ... - Insights IAS - November 23rd, 2023
- The Paul G. Allen Family Foundation awards $10.5 million to new ... - EurekAlert - November 23rd, 2023
- Daily briefing: Why these PhD scientists went into teaching - Nature.com - November 23rd, 2023
- Innovative Therapy Targets Rare, Hereditary Diseases - Mirage News - November 23rd, 2023
- Scientists uncover "genomic tug of war" that influences ... - News-Medical.Net - November 21st, 2023
- DOT1L is a barrier to histone acetylation during reprogramming to ... - Science - November 21st, 2023
- Tumor microenvironment composition & related therapy in HCC | JHC - Dove Medical Press - November 21st, 2023
- T-Therapeutics raises $59M in series A for T-cell receptors - BioWorld Online - November 19th, 2023
- A $3bn bet on finding the fountain of youth | Mint - Mint - November 19th, 2023
- A better way to study Parkinson's disease in the lab could lead to ... - EurekAlert - November 17th, 2023
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by ... - GlobeNewswire - November 17th, 2023
- MKL/SRF and Bcl6 mutual transcriptional repression safeguards the ... - Science - November 17th, 2023
- METTL1-Related Genes and Immune Characteristics in SLE | JIR - Dove Medical Press - November 17th, 2023
Recent Comments